Why this message is appearing and what you can do to make your experience on this site better.Select Journal or Resource JAMA & Archives Home JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology OtolaryngologyHead & Neck Surgery Pediatrics Nancy R.ScD; J.Gaziano, MD, MPH; Elaine Zaharris, BA; Jean MacFadyen, BA; Eleanor Danielson, MIA; Julie E.ScD; JoAnn E.MD, DrPH _JAMA. CONTEXT Recent randomized trials among patients with preexisting cardiovascular disease (CVD) have failed to support benefits of B-vitamin supplementation on cardiovascular risk.Data suggest benefits may be greater among women, yet women have been underrepresented in published randomized trials.OBJECTIVE To test whether abination of folic acid, vitamin B6, and vitamin B12 lowers risk of CVD among high-risk women with and without CVD.DESIGN, SETTING, AND PARTICIPANTS Within an ongoing randomized trial of antioxidant vitamins, 5442 women who were US health professionals aged 42 years or older, with either a history of CVD or 3 or more coronary risk factors, were enrolled in a randomized, double-blind, placebo-controlled trial to receive abination pill containing folic acid, vitamin B6, and vitamin B12 or a matching placebo, and were treated for 7.From April 1998 through July 2005.INTERVENTION Daily intake of abination pill of 2.Of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12.MAIN OUE MEASURES Aposite oue of myocardial infarction, stroke, coronary revascularization, or CVD mortality.RESULTSpared with placebo, a total of 796 women experienced a confirmed CVD event (406 in the active group and 390 in the placebo group).Receiving active vitamin treatment had similar risk for theposite CVD primary end point (226.Person-years vs 219.For the active vs placebo group; relative risk , 0.= .Well as for the secondary oues including myocardial infarction (34.Person-years vs 39.RR, 0.CI, 0._P_ = .(41.Person-years vs 36.Person-years; RR, 1.CI, 0._P_ = .CVD mortality (50.Person-years vs 49.Person-years; RR, 1.CI, 0._P_ = .In a blood substudy, geometric mean plasma homocysteine level was decreased by 18.CI, 12._P_ < .The active group (n = 150) over that observed in the placebo group (n = 150), for a difference of 2.(95% CI, 1. CONCLUSION After 7.Of treatment and follow-up, abination pill of folic acid, vitamin B6, and vitamin B12 did not reduce abined end point of total cardiovascular events among high-risk women, despite significant homocysteine lowering.TRIAL REGISTRATION clinicaltrials.AUTHOR AFFILIATIONS: Divisions of Preventive Medicine (Drs Albert, Cook, Gaziano, Buring, and Manson and Mss Zaharris, MacFadyen, and Danielson), Cardiovascular Medicine (Drs Albert and Gaziano), and Aging (Drs Gaziano and Buring), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Veterans Affairs Boston Healthcare System, Boston, Massachusetts (Dr Gaziano); Department of Ambulatory Care and Prevention, Harvard Medical School (Dr Buring); and Department of Epidemiology, Harvard School of Public Health, Boston (Drs Cook, Buring, and Manson).RELATED ARTICLE HOMOCYSTEINE-LOWERING B VITAMIN THERAPY IN CARDIOVASCULAR PREVENTIONWRONG AGAIN?Lonn _JAMA. THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES HOMOCYSTEINE-LOWERING B VITAMIN THERAPY IN CARDIOVASCULAR PREVENTIONWRONG AGAIN?Read more Intensive insulin therapy protects kidneys in critically ill patients
Get more Abbott's investigational simcor offers comparable ldl lowering to simvastatin and significantly raises hdl and lowers triglycerides in phase iii study
